2:00 PM
 | 
Aug 17, 2017
 |  BC Innovations  |  Translation in Brief

Stopping the invasion

How targeting the IRF3 pathway could prevent GBM recurrence

A team from the Netherlands Cancer Institute (NKI) has identified a network of extracellular matrix proteins that drives glioblastoma invasiveness and a master switch -- interferon regulatory factor 3 (IRF3) -- that can turn it off. The group believes combining IRF3 activation with standard of care could prevent recurrence.

In a Cell Reports study in July, the NKI team, led by Olaf van Tellingen and René Bernards, developed a new in vitro model of glioblastoma multiforme (GBM) invasiveness and used it identify subpopulations of cells within patient-derived GBM cell lines that were more aggressively invasive than others.

Tellingen is a group leader at NKI. Bernards is head of the institute's Division of Molecular Carcinogenesis and CSO and co-founder of diagnostics play Agendia N.V.

In the 3-D model, the patient-derived cell lines were...

Read the full 668 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >